Biologic drugs
PreclinicalBiologic
Biologic drugs is one of 6 biologic programs targeting Vogt-Koyanagi-Harada disease. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Vogt-Koyanagi-Harada Disease
#DrugCompanyPhaseTrials
1Kenalog
BBausch Health Americas, Inc.
Approved
Avastin
BBio-Thera Solutions
Phase 3
Cellcept
RochePreclinical
Humira
CCelltrion
Preclinical
Early Insertion
UUniversity of Sao Paulo
Preclinical
Biologic drugs
VVibeke Backer
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Vogt-Koyanagi-Harada disease1 trial
Outcome of Treatment of Uveitis With Biologic Drugs in Resistant Cases Vogt-koyanagi-Harada Disease
Unknown status·—··NCT05349747·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Biologic drugs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- VVibeke Backer